{"nctId":"NCT00694109","briefTitle":"An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia","startDateStruct":{"date":"2008-04"},"conditions":["Lipid Metabolism, Inborn Errors","Hypercholesterolemia, Autosomal Dominant","Hyperlipidemias","Metabolic Diseases","Hyperlipoproteinemia Type II","Metabolism, Inborn Errors","Genetic Diseases, Inborn","Infant, Newborn, Diseases","Metabolic Disorder","Congenital Abnormalities","Hypercholesterolemia","Hyperlipoproteinemias","Dyslipidemias","Lipid Metabolism Disorders"],"count":144,"armGroups":[{"label":"Mipomersen","type":"EXPERIMENTAL","interventionNames":["Drug: Mipomersen Sodium"]}],"interventions":[{"name":"Mipomersen Sodium","otherNames":["ISIS 301012","KynamroÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Satisfactory completion of dosing in their initial study (Protocol 301012-CS5 \\[NCT00607373\\], 301012-CS7 \\[NCT00706849\\], 301012-CS17 \\[NCT00477594\\], or MIPO3500108 \\[NCT00794664\\])\n\nExclusion Criteria:\n\n* Had any new condition or worsening of existing condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in Apolipoprotein B (Apo B)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.46","spread":null}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in Total Cholesterol","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":null}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non-HDL-C)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL Particles' Size (Total)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL Particles' Size (Large)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL Particles' Size (Medium)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL Particles' Size (Small)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL Particles' Size (Very Small)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL Particles' Size (Large)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL Particles' Size (Medium)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"838.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"388.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"233.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL Particles' Size (Small)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Intermediate Density Lipoprotein Particles' Size","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.46","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Particles' Size (Large) and Chylomicron Particles' Size","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"241.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in VLDL Particles' Size (Medium)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"172.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in VLDL Particles' Size (Small)","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total VLDL Particles' Size and Chylomicron Particles' Size","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.69","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in C-Reactive Protein","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein A-1","description":"Baseline was defined as the last value prior to receiving the first dose of mipomersen in this study (for participants randomized to placebo in their index study and for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\>=6 months from their last dose of mipomersen in their index study), or the last value prior to receiving the first dose of mipomersen in their index study (for participants randomized to mipomersen in their index study and their first dose of mipomersen in this study was administered \\<6 months from their last dose of mipomersen in their index study).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.67","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":141},"commonTop":["Injection site erythema","Injection site pain","Injection site bruising","Influenza like illness","Injection site discolouration"]}}}